Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

The New England journal of medicine·2026
Same authorSame journal

Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026

相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.6K

基因组学定义了髓瘤前体条件中的恶性转变.

Francesco Maura1, P Leif Bergsagel2, Bachisio Ziccheddu1,3

  • 1Memorial Sloan Kettering Cancer Center, New York, NY.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
|October 8, 2025
PubMed
概括

研究人员确定了基因组标记物,以区分具有不明意义的恶性和前恶性单克隆性胃病变 (MGUS) 和燃烧的多发性髓瘤 (SMM). 这种基因组分类完善了多发性骨髓瘤 (MM) 前体条件的风险分层.

更多相关视频

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.8K

相关实验视频

Last Updated: Jan 15, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.6K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.8K

科学领域:

  • 血液学 血液学 血液学
  • 基因组学就是基因组学.
  • 在瘤学瘤学.

背景情况:

  • 多发性骨髓瘤 (MM) 从前体条件中发展:意义不明的单克隆性骨髓瘤病变 (MGUS) 和燃烧的多发性骨髓瘤 (SMM).
  • 目前的方法无法可靠地区分具有高进展风险的MM前体疾病和不太可能进展的MM前体疾病.
  • 从MGUS/SMM恶性转变为MM目前由末端器官损伤来定义,而不是内在的生物学差异.

研究的目的:

  • 开发基因组标准,用于识别MGUS和SMM的恶性转变.
  • 区分生物恶性 (基因组MM) 和前恶性 (基因组MGUS) 的前体条件子集.
  • 改善MGUS和SMM患者的风险分层.

主要方法:

  • 分析了374名患有MGUS或SMM的患者的基因组数据 (277名培训,97名验证).
  • 引入基于独特的基因组特征的"基因组MM"和"基因组MGUS"概念.
  • 基因组特征与2/20/20国际髓瘤工作组模型的整合.

主要成果:

  • 基因组特征可以识别MGUS和SMM的恶性转变,将它们与前恶性状态区分开来.
  • 大多数SMM病例表现出恶性转变 (基因组MM) 的基因组特征,这表明进展风险很高.
  • 显著比例的MGUS (60%) 和SMM (10%) 缺乏恶性基因组特征 (基因组MGUS) 并没有进展.
  • 基因组标准与2/20/20模型相结合,显著改善了进展预测.

结论:

  • 基因组分析提供了一种新的方法来分类和分层MM前体条件中的风险.
  • 基因组MM和基因组MGUS的概念为风险评估提供了生物学基础.
  • 这种基因组分类有可能完善MGUS和SMM的患者管理和监测.